Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis

19 Oct 2021

Abstract excerpt

Background and Objectives Costimulation by CD40 and its ligand CD40L (CD154) is important for the functional differentiation of T cells. Preclinical studies have recognized the importance of this costimulatory interaction in the pathogenesis of experimental models of multiple sclerosis (MS). To determine safety, pharmacokinetics, and immune effect of a humanized monoclonal antibody (mAb) against CD40 ligand...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Multiple Sclerosis Research Studies
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34654708
DOI: 10.1212/nxi.0000000000001096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Immune Effects of Blocking CD40 Ligand in Multiple SclerosisPMID 34654708Read ↗

Multimodal Effects of CD40L Blockade in Multiple Sclerosis: Insights from Preclinical and Clinical StudiesSemantic proximity Read ↗

Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosisSemantic proximity Read ↗

Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisSemantic proximity Read ↗

Cladribine: mechanisms and mysteries in multiple sclerosisSemantic proximity Read ↗

Natalizumab restores aberrant mi<scp>RNA</scp>expression profile in multiple sclerosis and reveals a critical role for miR‐20bSemantic proximity Read ↗

Natalizumab effects on immune cell responses in multiple sclerosis.Semantic proximity Read ↗

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.Semantic proximity Read ↗

A novel human truncated IL12rβ1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation.Semantic proximity Read ↗

Immune surveillance in multiple sclerosis patients treated with natalizumab.Semantic proximity Read ↗

Comparative effectiveness of natalizumab and fingolimod and injectable therapies in patients with pediatric multiple sclerosis: A registry-based retrospective cohort studySemantic proximity Read ↗

T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.Semantic proximity Read ↗

The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.